Last 12 months
Inside the activity.
0 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 12 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2023 Filed Mar 2, 2023 16:58 UTC |
Weinberg UriChief Innovation Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 21,607 | $76.97 Strike: $76.97 | $1,663,090.79 |
DisclosureSEC source: 0001645113-23-000029 · wf-form4_167779429653064.xml · derivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,607 Underlying: Ordinary Shares · 21,607 shares Expires 2033-02-27 F2 · derivative.exercise_date: Options to buy 21,607 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:58 UTC |
Weinberg UriChief Innovation Officer
|
GrantOrdinary Shares | 12,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000029 · wf-form4_167779429653064.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,278 F1 · shares: Represents restricted share units that are scheduled to vest on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:01 UTC |
Leonard Frank XPresident, CNS Cancers US
|
GrantOptions to Buy Ordinary Shares · Derivative | 30,971 | $76.97 Strike: $76.97 | $2,383,837.87 |
DisclosureSEC source: 0001645113-23-000031 · wf-form4_167779444622406.xml · derivative · entry 3 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,971 Underlying: Ordinary Shares · 30,971 shares Expires 2033-02-27 F3 · derivative.exercise_date: Options to buy 30,971 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:01 UTC |
Leonard Frank XPresident, CNS Cancers US
|
GrantOrdinary Shares | 18,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000031 · wf-form4_167779444622406.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,779 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:00 UTC |
Shah PriteshChief Growth Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 31,691 | $76.97 Strike: $76.97 | $2,439,256.27 |
DisclosureSEC source: 0001645113-23-000030 · wf-form4_167779437669900.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,691 Underlying: Ordinary Shares · 31,691 shares Expires 2033-02-27 F3 · derivative.exercise_date: Options to buy 31,691 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:00 UTC |
Shah PriteshChief Growth Officer
|
GrantOrdinary Shares | 19,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000030 · wf-form4_167779437669900.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,898 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:56 UTC |
Ben Arye BarakGeneral Counsel
|
GrantOrdinary Shares · Derivative | 29,531 | $76.97 Strike: $76.97 | $2,273,001.07 |
DisclosureSEC source: 0001645113-23-000028 · wf-form4_167779418753921.xml · derivative · entry 2 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,531 Underlying: Ordinary Shares · 29,531 shares Expires 2033-02-27 F2 · derivative.exercise_date: Options to buy 29,531 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:56 UTC |
Ben Arye BarakGeneral Counsel
|
GrantOrdinary Shares | 17,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000028 · wf-form4_167779418753921.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,907 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:55 UTC |
Cordova AshleyChief Financial Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 39,614 | $76.97 Strike: $76.97 | $3,049,089.58 |
DisclosureSEC source: 0001645113-23-000027 · wf-form4_167779410749716.xml · derivative · entry 3 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,614 Underlying: Ordinary Shares · 39,614 shares Expires 2033-02-27 F3 · derivative.exercise_date: Options to buy 39,614 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:55 UTC |
Cordova AshleyChief Financial Officer
|
GrantOrdinary Shares | 23,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000027 · wf-form4_167779410749716.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,260 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:49 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 36,013 | $76.97 Strike: $76.97 | $2,771,920.61 |
DisclosureSEC source: 0001645113-23-000025 · wf-form4_167779374758834.xml · derivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,013 Underlying: Ordinary Shares · 36,013 shares Expires 2033-02-27 F3 · derivative.exercise_date: Options to buy 36,013 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:49 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
GrantOrdinary Shares | 21,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000025 · wf-form4_167779374758834.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,779 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
GrantOrdinary Shares | 39 | $62.31 | $2,429.90 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 13 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,622 F11 · price: In accordance with the issuer's Employee Share Purchase Plan, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 16:13 UTC |
Burke William PatrickChief Human Resources Officer
|
GrantOrdinary Shares | 108 | $62.31 | $6,728.94 |
DisclosureSEC source: 0001645113-23-000011 · wf-form4_167338521511152.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,594 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:20 UTC |
Ben Arye BarakGeneral Counsel
|
GrantOrdinary Shares | 150 | $62.31 | $9,345.75 |
DisclosureSEC source: 0001645113-23-000015 · wf-form4_167338563438202.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,152 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:18 UTC |
Cordova AshleyChief Financial Officer
|
GrantOrdinary Shares | 66 | $62.31 | $4,112.13 |
DisclosureSEC source: 0001645113-23-000014 · wf-form4_167338547170322.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,442 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:17 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
GrantOrdinary Shares | 102 | $62.31 | $6,355.11 |
DisclosureSEC source: 0001645113-23-000013 · wf-form4_167338542046628.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,126 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:14 UTC |
Benaim ElyChief Medical Officer
|
GrantOrdinary Shares | 98 | $62.31 | $6,105.89 |
DisclosureSEC source: 0001645113-23-000012 · wf-form4_167338526960077.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,770 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC |
Weinberg UriChief Science Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,946 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · derivative · entry 6 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946 Underlying: Ordinary Shares · 1,946 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC |
Weinberg UriChief Science Officer
|
SaleOrdinary Shares | 1,201 | $120.00 | $144,120.00 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · nonDerivative · entry 5 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,286 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC |
Weinberg UriChief Science Officer
|
SaleOrdinary Shares | 2,617 | $108.00 | $282,636.00 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · nonDerivative · entry 4 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,487 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC |
Weinberg UriChief Science Officer
|
SaleOrdinary Shares | 1,946 | $120.00 | $233,520.00 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · nonDerivative · entry 3 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,104 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC |
Weinberg UriChief Science Officer
|
Exercise / conversionOrdinary Shares | 1,946 | $47.04 | $91,539.84 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC |
Weinberg UriChief Science Officer
|
SaleOrdinary Shares | 2,379 | $120.00 | $285,480.00 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,104 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:20 UTC |
Shah PriteshChief Commercial Officer
|
SaleOrdinary Shares | 387 | $108.00 | $41,796.00 |
DisclosureSEC source: 0001645113-23-000008 · wf-form4_167330639201251.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,843 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,183 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · derivative · entry 19 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,662 Underlying: Ordinary Shares · 7,183 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,183 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · derivative · entry 18 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,479 Underlying: Ordinary Shares · 7,183 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,517 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · derivative · entry 17 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,517 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,500 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · derivative · entry 16 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,500 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,826 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · derivative · entry 15 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,826 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 7,183 | $120.00 | $861,960.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 14 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
Exercise / conversionOrdinary Shares | 7,183 | $21.15 | $151,920.45 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 13 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 7,183 | $114.00 | $818,862.72 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 12 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F4 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 7,183 shares in multiple trades at prices ranging from $114.00 to $114.03. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
Exercise / conversionOrdinary Shares | 7,183 | $21.15 | $151,920.45 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 11 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 5,517 | $108.00 | $595,836.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 10 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
Exercise / conversionOrdinary Shares | 5,517 | $7.15 | $39,446.55 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 9 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 7,500 | $108.00 | $810,000.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 8 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
Exercise / conversionOrdinary Shares | 7,500 | $11.46 | $85,950.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 7 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 7,826 | $108.00 | $845,208.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 6 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
Exercise / conversionOrdinary Shares | 7,826 | $14.37 | $112,459.62 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 5 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 1,010 | $117.00 | $118,170.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 4 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 526 | $115.03 | $60,508.30 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,168 F3 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 526 shares in multiple trades at prices ranging from $115.00 to $115.59. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 417 | $108.00 | $45,036.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,694 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 2,345 | $119.01 | $279,073.06 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,111 F1 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 2,345 shares in multiple trades at prices ranging from $119.00 to $119.07. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 187,500 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · derivative · entry 15 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 187,500 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. F12 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 25,000 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · derivative · entry 14 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 25,000 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. F12 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
SaleOrdinary Shares | 187,500 | $108.00 | $20,250,000.00 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 12 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,583 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
Exercise / conversionOrdinary Shares | 187,500 | $7.15 | $1,340,625.00 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 11 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
SaleOrdinary Shares | 500 | $119.99 | $59,993.50 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 10 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,583 F10 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 500 shares in multiple trades at prices ranging from $119.98 to $120.00. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
SaleOrdinary Shares | 1,344 | $119.35 | $160,405.46 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 9 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,083 F9 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,344 shares in multiple trades at prices ranging from $118.95 to $119.84. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.